Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mark McDonough, Judd Jessup

Premium

Mark McDonough will become CEO of CombiMatrix when Judd Jessup retires on March 15, the molecular diagnostics firm said last week. McDonough is currently the chief commercial officer at CombiMatrix. Before joining the firm last year, he was vice president of sales, customer service, and training at Pathwork Diagnostics, another molecular diagnostics firm that specializes in microarray-based tests.

CombiMatrix appointed Jessup CEO in 2010. In recent years, he has refocused the company on prenatal and pediatric microarray-based cytogenetic testing. In a statement, Jessup portrayed his role at CombiMatrix as leading its transition to a "pure-play diagnostics lab." Calling that transition complete, he said that the company will be in "very capable hands" under McDonough's leadership.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.